C3 looks to Chinese market with Helicon

Clinical Cell Culture Ltd has announced the appointment of Perth-based North Asia-specialist Helicon Group Ltd as its distributor of its ReCell skin regeneration product in China.

C3 said Helicon will act through its Chinese partner Cobra Bio Health Services International.

The arrangement follows C3's recent announcement that it had secured a Korean manufacturer for another of its skin products.

Helicon is an Australian registered and headquartered company established specifically to identify and exploit
niche market opportunities in the biomedical markets of North Asia, particularly China and to participate in the
significant growth that has been projected for these markets over the next 25 years